Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsHo, Jennifer E
Larson, Martin G
McCabe, Elizabeth L
Johnson, Andrew D
O'Donnell, Christopher J
Felix, Janine F
Schreiter, Eric R
Vasan, Ramachandran S
Januzzi, James L
Lee, Richard T
Wang, Thomas J
Assimes, Themistocles L
König, Inke R
Reilly, Muredach P
Samani, Nilesh J
Stewart, Alexandre F R
MetadataShow full item record
CitationJ. Clin. Invest.123 (10):4208-18
AbstractThe suppression of tumorigenicity 2/IL-33 (ST2/IL-33) pathway has been implicated in several immune and inflammatory diseases. ST2 is produced as 2 isoforms. The membrane-bound isoform (ST2L) induces an immune response when bound to its ligand, IL-33. The other isoform is a soluble protein (sST2) that is thought to be a decoy receptor for IL-33 signaling. Elevated sST2 levels in serum are associated with an increased risk for cardiovascular disease. We investigated the determinants of sST2 plasma concentrations in 2,991 Framingham Offspring Cohort participants. While clinical and environmental factors explained some variation in sST2 levels, much of the variation in sST2 production was driven by genetic factors. In a genome-wide association study (GWAS), multiple SNPs within IL1RL1 (the gene encoding ST2) demonstrated associations with sST2 concentrations. Five missense variants of IL1RL1 correlated with higher sST2 levels in the GWAS and mapped to the intracellular domain of ST2, which is absent in sST2. In a cell culture model, IL1RL1 missense variants increased sST2 expression by inducing IL-33 expression and enhancing IL-33 responsiveness (via ST2L). Our data suggest that genetic variation in IL1RL1 can result in increased levels of sST2 and alter immune and inflammatory signaling through the ST2/IL-33 pathway.
DescriptionTo access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to The Journal of clinical investigation
- A functional IL1RL1 variant regulates corticosteroid-induced sST2 expression in ulcerative colitis.
- Authors: Díaz-Jiménez D, Núñez L, De la Fuente M, Dubois-Camacho K, Sepúlveda H, Montecino M, Torres-Riquelme A, García-González P, Chnaiderman J, Vossenkamper A, MacDonald TT, Simian D, González MJ, Cidlowski JA, Quera R, Hermoso MA
- Issue date: 2017 Aug 31
- Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature.
- Authors: Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, Zuckermann A, Aliabadi A, Gröger M, Maurer G, Huber K, Wojta J
- Issue date: 2013 Jul
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.
- Authors: Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT
- Issue date: 2007 Jun
- The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease.
- Authors: Miller AM, Liew FY
- Issue date: 2011 Aug
- ST2 Signaling in the Tumor Microenvironment.
- Authors: Chang CP, Hu MH, Hsiao YP, Wang YC
- Issue date: 2020